AADIAadi Bioscience, Inc.

Nasdaq aadibio.com


$ 1.83 $ -0.04 (-2.13 %)    

Tuesday, 17-Sep-2024 15:59:52 EDT
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 1.84
$ 1.83 x 400
$ 1.84 x 600
-- - --
$ 1.21 - $ 5.70
94,227
na
45.29M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-29-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-17-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-11-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-07-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-10-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-07-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-13-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-14-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-downgrades-aadi-bioscience-to-neutral-lowers-price-target-to-175

Piper Sandler analyst Joseph Catanzaro downgrades Aadi Bioscience (NASDAQ:AADI) from Overweight to Neutral and lowers the pr...

 cancer-focused-aadi-bioscience-stock-plunges-as-solid-tumor-trial-falls-short-of-expectations

Aadi Bioscience halts its PRECISION1 trial of nab-sirolimus in solid tumors with TSC1/TSC2 mutations due to insufficient effica...

 hc-wainwright--co-reiterates-neutral-on-aadi-bioscience

HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience (NASDAQ:AADI) with a Neutral.

 td-cowen-downgrades-aadi-bioscience-to-hold

TD Cowen analyst Boris Peaker downgrades Aadi Bioscience (NASDAQ:AADI) from Buy to Hold.

 aadi-bioscience-says-precision1-tumor-agnostic-trial-unlikely-to-meet-regulatory-threshold-to-support-accelerated-approval-and-will-be-halted

An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy thresho...

 aadi-bioscience-q2-2024-gaap-eps-054-beats-069-estimate-sales-6179m-miss-6197m-estimate-cash-and-equivalents-786m

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.6...

 hc-wainwright--co-reiterates-neutral-on-aadi-bioscience

HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience (NASDAQ:AADI) with a Neutral.

 aadi-bioscience-q1-2024-gaap-eps-068-misses-065-estimate-sales-5353m-miss-6454m-estimate

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0...

 reported-sunday-aadi-bioscience-presented-new-subgroup-analysis-of-patients-with-advanced-malignant-pecoma-of-gynecologic-origin-treated-with-nab-sirolimus-at-society-of-gynecologic-oncology

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gyneco...

 aadi-bioscience-q4-gaap-eps-060-beats-065-estimate-sales-633m-beat-629m-estimate

Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.6...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 aadi-bioscience-earnings-preview
Aadi Bioscience Earnings Preview
03/12/2024 17:01:21

 why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

 why-biovie-shares-are-trading-lower-by-around-42-here-are-20-stocks-moving-premarket

Shares of BioVie Inc. (NASDAQ: BIVI) fell sharply in today’s pre-market trading after the company reported pricing of public ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION